<p>Artivion, Inc.（紐約證券交易所代碼：AORT - 獲取免費報告）的股票在目前覆蓋該股票的九家券商中獲得了 “適度買入” 的共識推薦，Marketbeat 報道稱。一位研究分析師對該股票給予了賣出評級，一位給予了持有評級，七位給予了買入評級。在過去一年中更新了對該股票覆蓋的券商中，平均一年目標價為 49.1143 美元。</p>
<p>AORT 已成為多份研究分析師報告的主題。華爾街禪在 12 月 21 日的研究報告中將 Artivion 的股票評級從 “買入” 上調至 “強力買入”。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Artivion 股票的 “賣出（d-）” 評級。Needham &amp; Company LLC 在 11 月 7 日的報告中將 Artivion 的目標價從 50.00 美元上調至 58.00 美元，並給予該股票 “買入” 評級。Canaccord Genuity Group 在 12 月 17 日的研究報告中重新發布了 “買入” 評級，並對 Artivion 股票設定了 51.00 美元的目標價。最後，JMP Securities 在 10 月 10 日的研究報告中將 Artivion 的目標價從 42.00 美元上調至 47.00 美元，並給予該股票 “市場表現優於大盤” 評級。</p>
<p><strong>閲讀我們關於 Artivion 的最新研究報告</strong></p>
<h2>Artivion 的內部買賣</h2>
<p>在其他新聞中，首席執行官 James P. Mackin 於 11 月 13 日星期四出售了 34,210 股公司的股票。股票以平均價格 45.86 美元出售，總價值為 1,568,870.60 美元。交易後，首席執行官持有 800,993 股公司股票，估值約為 36,733,538.98 美元。此交易代表其持股比例下降了 4.10%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，副總裁 Marshall S. Stanton 於 11 月 21 日星期五出售了 47,376 股公司的股票。該股票以平均價格 45.04 美元出售，總交易額為 2,133,815.04 美元。出售後，副總裁直接持有 44,753 股公司的股票，估值約為 2,015,675.12 美元。此交易代表其持股比例下降了 51.42%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售 234,511 股公司股票，價值 10,612,452 美元。公司內部人士目前持有 8.10% 的股票。</p>
<h2>機構投資者對 Artivion 的看法</h2>
<p>幾家大型投資者最近買入和賣出了該公司的股票。Aster Capital Management DIFC Ltd 在第三季度將其在 Artivion 的持股比例提高了 402.3%。Aster Capital Management DIFC Ltd 目前擁有 648 股公司股票，價值 27,000 美元，此前在上個季度購買了 519 股。Caitong International Asset Management Co. Ltd 在第三季度購買了 Artivion 的新股份，價值約為 27,000 美元。Smartleaf Asset Management LLC 在第二季度將其在 Artivion 的持股比例提高了 47.7%。Smartleaf Asset Management LLC 目前擁有 1,667 股公司股票，估值為 52,000 美元，此前在此期間又收購了 538 股。懷俄明州購買了 Artivion 的新股份，價值約為 80,000 美元。最後，Quadrant Capital Group LLC 在第三季度購買了 Artivion 的新股份，價值約為 92,000 美元。機構投資者持有公司 86.37% 的股票。</p>
<h2>Artivion 的價格表現</h2>
<p>Artivion 股票在週一開盤價為 44.27 美元。該公司的 50 日移動平均線為 45.70 美元，200 日移動平均線為 41.11 美元。該公司的債務與股本比率為 0.50，速動比率為 2.88，流動比率為 3.93。該公司的市值為 21 億美元，市盈率為-184.47，貝塔值為 1.59。Artivion 的 52 周最低價為 21.97 美元，52 周最高價為 48.25 美元。</p>
<p>Artivion（紐約證券交易所代碼：AORT - 獲取免費報告）最後一次公佈財報是在 11 月 6 日星期四。該公司報告本季度每股收益為 0.16 美元，超出分析師共識預期的 0.14 美元，超出幅度為 0.02 美元。該公司本季度的收入為 1.1339 億美元，而分析師預期為 1.1071 億美元。Artivion 的股本回報率為 5.98%，淨利潤率為-2.16%。該公司本季度的收入同比增長了 18.9%。股票研究分析師預測，Artivion 在當前財政年度將發佈 0.37 美元的每股收益。</p>
<h2>關於 Artivion</h2>
<p>（獲取免費報告）</p>
<p>Artivion, Inc NYSE: AORT 是一家全球醫療技術公司，開發、製造和銷售用於心臟和血管手術的可植入組織產品和外科設備。該公司的產品組合包括來自人類和動物組織的生物植入物，如同種移植物和異種移植物，以及合成支架和外科粘合劑。這些產品旨在在主動脈修復、心臟瓣膜手術和血管重建等手術中修復、加固或替換受損的心血管和胸部組織。</p>
<p>該公司最初成立於 1984 年，名為 CryoLife，並於 2022 年初更名為 Artivion，以反映其在心血管創新方面的更廣泛使命。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Artivion 更好</li>
<li>巨大的機器人推廣正在進行中</li>
<li>請勿刪除，立即閲讀</li>
<li>免費：可能改變您生活的加密峯會</li>
<li>新的黃金價格目標</li>
<li>家族信託如何幫助保護您的財富</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Artivion 嗎？</h2>
<p>在考慮 Artivion 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而 Artivion 並不在名單上。</p>
<p>雖然 Artivion 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AORT

<p>Artivion, Inc.（紐約證券交易所代碼：AORT）獲得了九家券商的 “適度買入” 共識評級。分析師給予了一項賣出、一項持有和七項買入評級，平均目標價為 49.11 美元。最近的內部交易包括首席執行官 James P. Mackin 出售 34,210 股，副總裁 Marshall S. Stanton 出售 47,376 股。機構投資者持有該股票的 86.37%。Artivion 報告上個季度每股收益為 0.16 美元，超出預期，收入同比增長 18.9%</p>

<p>Shares of Artivion, Inc. (NYSE:AORT - Get Free Report) have earned a consensus recommendation of &#34;Moderate Buy&#34; from the nine brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $49.1143.</p>
<div class="lb-trans"><p>Artivion, Inc.（紐約證券交易所代碼：AORT - 獲取免費報告）的股票在目前覆蓋該股票的九家券商中獲得了 “適度買入” 的共識推薦，Marketbeat 報道稱。一位研究分析師對該股票給予了賣出評級，一位給予了持有評級，七位給予了買入評級。在過去一年中更新了對該股票覆蓋的券商中，平均一年目標價為 49.1143 美元。</p>
</div><p>AORT has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Artivion from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Sunday, December 21st. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Artivion in a research report on Wednesday, October 8th. Needham &amp; Company LLC upped their price objective on Artivion from $50.00 to $58.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, November 7th. Canaccord Genuity Group reissued a &#34;buy&#34; rating and issued a $51.00 target price on shares of Artivion in a research note on Wednesday, December 17th. Finally, JMP Securities boosted their target price on Artivion from $42.00 to $47.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Friday, October 10th.</p>
<div class="lb-trans"><p>AORT 已成為多份研究分析師報告的主題。華爾街禪在 12 月 21 日的研究報告中將 Artivion 的股票評級從 “買入” 上調至 “強力買入”。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Artivion 股票的 “賣出（d-）” 評級。Needham &amp; Company LLC 在 11 月 7 日的報告中將 Artivion 的目標價從 50.00 美元上調至 58.00 美元，並給予該股票 “買入” 評級。Canaccord Genuity Group 在 12 月 17 日的研究報告中重新發布了 “買入” 評級，並對 Artivion 股票設定了 51.00 美元的目標價。最後，JMP Securities 在 10 月 10 日的研究報告中將 Artivion 的目標價從 42.00 美元上調至 47.00 美元，並給予該股票 “市場表現優於大盤” 評級。</p>
</div><p><strong>Read Our Latest Research Report on Artivion</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Artivion 的最新研究報告</strong></p>
</div><h2>Insider Buying and Selling at Artivion</h2>
<div class="lb-trans"><h2>Artivion 的內部買賣</h2>
</div><p>In other news, CEO James P. Mackin sold 34,210 shares of the firm's stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $45.86, for a total value of $1,568,870.60. Following the transaction, the chief executive officer owned 800,993 shares of the company's stock, valued at approximately $36,733,538.98. This trade represents a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, SVP Marshall S. Stanton sold 47,376 shares of the business's stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the sale, the senior vice president directly owned 44,753 shares of the company's stock, valued at approximately $2,015,675.12. This trade represents a 51.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 234,511 shares of company stock valued at $10,612,452. 8.10% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 James P. Mackin 於 11 月 13 日星期四出售了 34,210 股公司的股票。股票以平均價格 45.86 美元出售，總價值為 1,568,870.60 美元。交易後，首席執行官持有 800,993 股公司股票，估值約為 36,733,538.98 美元。此交易代表其持股比例下降了 4.10%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，副總裁 Marshall S. Stanton 於 11 月 21 日星期五出售了 47,376 股公司的股票。該股票以平均價格 45.04 美元出售，總交易額為 2,133,815.04 美元。出售後，副總裁直接持有 44,753 股公司的股票，估值約為 2,015,675.12 美元。此交易代表其持股比例下降了 51.42%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去 90 天內，內部人士已出售 234,511 股公司股票，價值 10,612,452 美元。公司內部人士目前持有 8.10% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Artivion</h2>
<div class="lb-trans"><h2>機構投資者對 Artivion 的看法</h2>
</div><p>Several large investors have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd boosted its position in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company's stock worth $27,000 after purchasing an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Artivion during the third quarter worth about $27,000. Smartleaf Asset Management LLC grew its stake in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after acquiring an additional 538 shares during the period. State of Wyoming bought a new stake in shares of Artivion in the third quarter worth about $80,000. Finally, Quadrant Capital Group LLC bought a new stake in shares of Artivion in the third quarter worth about $92,000. Institutional investors own 86.37% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近買入和賣出了該公司的股票。Aster Capital Management DIFC Ltd 在第三季度將其在 Artivion 的持股比例提高了 402.3%。Aster Capital Management DIFC Ltd 目前擁有 648 股公司股票，價值 27,000 美元，此前在上個季度購買了 519 股。Caitong International Asset Management Co. Ltd 在第三季度購買了 Artivion 的新股份，價值約為 27,000 美元。Smartleaf Asset Management LLC 在第二季度將其在 Artivion 的持股比例提高了 47.7%。Smartleaf Asset Management LLC 目前擁有 1,667 股公司股票，估值為 52,000 美元，此前在此期間又收購了 538 股。懷俄明州購買了 Artivion 的新股份，價值約為 80,000 美元。最後，Quadrant Capital Group LLC 在第三季度購買了 Artivion 的新股份，價值約為 92,000 美元。機構投資者持有公司 86.37% 的股票。</p>
</div><h2>Artivion Price Performance</h2>
<div class="lb-trans"><h2>Artivion 的價格表現</h2>
</div><p>Artivion stock opened at $44.27 on Monday. The business's fifty day moving average is $45.70 and its two-hundred day moving average is $41.11. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93. The firm has a market cap of $2.10 billion, a P/E ratio of -184.47 and a beta of 1.59. Artivion has a 52 week low of $21.97 and a 52 week high of $48.25.</p>
<div class="lb-trans"><p>Artivion 股票在週一開盤價為 44.27 美元。該公司的 50 日移動平均線為 45.70 美元，200 日移動平均線為 41.11 美元。該公司的債務與股本比率為 0.50，速動比率為 2.88，流動比率為 3.93。該公司的市值為 21 億美元，市盈率為-184.47，貝塔值為 1.59。Artivion 的 52 周最低價為 21.97 美元，52 周最高價為 48.25 美元。</p>
</div><p>Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The firm's revenue for the quarter was up 18.9% on a year-over-year basis. Equities research analysts forecast that Artivion will post 0.37 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Artivion（紐約證券交易所代碼：AORT - 獲取免費報告）最後一次公佈財報是在 11 月 6 日星期四。該公司報告本季度每股收益為 0.16 美元，超出分析師共識預期的 0.14 美元，超出幅度為 0.02 美元。該公司本季度的收入為 1.1339 億美元，而分析師預期為 1.1071 億美元。Artivion 的股本回報率為 5.98%，淨利潤率為-2.16%。該公司本季度的收入同比增長了 18.9%。股票研究分析師預測，Artivion 在當前財政年度將發佈 0.37 美元的每股收益。</p>
</div><h2>About Artivion</h2>
<div class="lb-trans"><h2>關於 Artivion</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.</p>
<div class="lb-trans"><p>Artivion, Inc NYSE: AORT 是一家全球醫療技術公司，開發、製造和銷售用於心臟和血管手術的可植入組織產品和外科設備。該公司的產品組合包括來自人類和動物組織的生物植入物，如同種移植物和異種移植物，以及合成支架和外科粘合劑。這些產品旨在在主動脈修復、心臟瓣膜手術和血管重建等手術中修復、加固或替換受損的心血管和胸部組織。</p>
</div><p>Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.</p>
<div class="lb-trans"><p>該公司最初成立於 1984 年，名為 CryoLife，並於 2022 年初更名為 Artivion，以反映其在心血管創新方面的更廣泛使命。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Artivion</li>
<li>Huge robotics rollout underway</li>
<li>Do not delete, read immediately</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>New gold price target</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Artivion 更好</li>
<li>巨大的機器人推廣正在進行中</li>
<li>請勿刪除，立即閲讀</li>
<li>免費：可能改變您生活的加密峯會</li>
<li>新的黃金價格目標</li>
<li>家族信託如何幫助保護您的財富</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFPUlQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=AORT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Artivion Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Artivion 嗎？</h2>
</div><p>Before you consider Artivion, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Artivion 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而 Artivion 並不在名單上。</p>
</div><p>While Artivion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Artivion 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Artivion, Inc.（NYSE 代碼：AORT）被分析師給予 “適度買入” 的平均評級